ERBB2 and neoplasm: After T-DXd is internalized into tumor cells, the toxic payload, DXd, is released and can permeate through the cell membrane to neighboring tumor cells, regardless of their HER2 status; this feature has resulted in T-DXd demonstrating clinical efficacy in heterogenous HER2 tumors [35].